<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Triptans (serotonin 1b/1d agonists) for acute treatment of adults with migraine</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Triptans (serotonin 1b/1d agonists) for acute treatment of adults with migraine</h1>
<div class="graphic"><div class="figure"><div class="ttl">Triptans (serotonin 1b/1d agonists) for acute treatment of adults with migraine</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="17%"></colgroup> <colgroup width="32%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td class="subtitle1">Triptan</td> <td class="subtitle1">Route (preparations)</td> <td class="subtitle1">Typical initial dose</td> <td class="subtitle1">Maximum dose per 24 hours</td> <td class="subtitle1">Notes</td> </tr> <tr> <td class="divider_bottom" rowspan="6">Sumatriptan</td> <td>Oral (tablet)</td> <td>50 to 100 mg</td> <td>200 mg</td> <td>Â </td> </tr> <tr> <td>SUBQ (solution for injection)</td> <td>6 mg</td> <td>12 mg</td> <td> <ul> <li>More efficacious than oral route with greater adverse effects</li> <li>May repeat dose after 1 hour</li> <li>If 6 mg dose is not tolerated, may use reduced dose (eg, 3 or 4 mg)</li> <li>Autoinjectors (3 mg, 4 mg, or 6 mg) are also available</li> </ul> </td> </tr> <tr> <td colspan="3">Intranasal (spray and powder)</td> <td class="divider_bottom" rowspan="4"> <ul> <li>DDM additive increases rate of absorption; nasal spray coformulated with DDM is used at a lower dose (ie, 10 mg), which may be repeated after 1 hour</li> </ul> </td> </tr> <tr> <td class="indent1">Spray (Imitrex and generics)</td> <td>20 mg in one nostril</td> <td>40 mg</td> </tr> <tr> <td class="indent1">Spray (coformulated with DDM; Tosymra)</td> <td>10 mg in one nostril</td> <td>30 mg</td> </tr> <tr class="divider_bottom"> <td class="indent1">Powder</td> <td>22 mg (11 mg capsule insufflated in each nostril)</td> <td>44 mg</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Zolmitriptan</td> <td>Oral (tablet and ODT)</td> <td>2.5 to 5 mg</td> <td>10 mg</td> <td> <ul> <li>Oral tablet (but not ODT) may be split to achieve smaller dose</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Intranasal (solution)</td> <td>2.5 or 5 mg in one nostril</td> <td>10 mg</td> <td> <ul> <li>Less taste disturbance than intranasal sumatriptan</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Eletriptan</td> <td>Oral (tablet)</td> <td>20 to 40 mg</td> <td>80 mg</td> <td> <ul> <li>In general, 40 mg dose is recommended due to greater efficacy, however 20 mg may be better tolerated</li> <li>Metabolized by CYP3A4; do not use within 72 hours of a CYP3A4 inhibitor*</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Rizatriptan</td> <td>Oral (tablet, ODT, film)</td> <td> <p>Tablet, ODT: 5 to 10 mg</p> Film: 10 mg </td> <td>30 mg</td> <td> <ul> <li>Use reduced dose in patients taking propranolol*</li> <li>Do not split 10 mg film to achieve a smaller dose</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Almotriptan</td> <td>Oral (tablet)</td> <td>12.5 mg</td> <td>25 mg</td> <td> <ul> <li>May be better tolerated than many other triptans</li> <li>Metabolized by CYP3A4; dose adjustment or avoidance may be required with CYP3A4 inhibitors*</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Naratriptan</td> <td>Oral (tablet)</td> <td>2.5 mg</td> <td>5 mg</td> <td> <ul> <li>Slower onset and longer duration of effect than many other triptans</li> <li>May have lower efficacy but be better tolerated than many other triptans</li> <li>May repeat dose after 4 hours</li> </ul> </td> </tr> <tr> <td>Frovatriptan</td> <td>Oral (tablet)</td> <td>2.5 mg</td> <td>5 mg</td> <td> <ul> <li>Slower onset and longer duration of effect than many other triptans</li> <li>May have lower efficacy but be better tolerated than many other triptans</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Several triptans are effective options for acute treatment of migraine. Choice of triptan should be individualized; patients who do not respond well to one triptan may respond to another. For patients using a triptan, treatment should be started early after onset of migraine symptoms. Dose may be repeated after two hours if response to initial dose is suboptimal, unless otherwise noted, up to the maximum dose in a 24-hour period. Triptans should not be administered within 24-hour use of another triptan or ergotamine agents. Limit use to less than 10 days per month to avoid medication-overuse headache. Triptans should be avoided for patients with hemiplegic migraine or migraine with brainstem aura and those with a history of ischemic stroke, ischemic heart disease, uncontrolled hypertension, and pregnancy. Refer to UpToDate for additional details.</div><div class="graphic_footnotes"><p>SUBQ: subcutaneous; DDM: n-Dodecyl beta-D-maltoside; ODT: orally disintegrating tablet; CYP3A4: cytochrome P450 isoenzyme 3A4.</p>
* Refer to <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> database for specific recommendations.</div><div id="graphicVersion">Graphic 141582 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
